Indivior plc is a specialty pharmaceutical company dedicated to developing and commercializing treatments for opioid use disorder and other addiction-related conditions. Established in 2014 as a spin-off from Reckitt Benckiser’s healthcare division, Indivior has since focused its efforts on advancing patient access to evidence-based therapies that address the global opioid crisis. The company is headquartered in Richmond, Virginia, and operates research and development facilities in the United States and Europe.
The company’s flagship products include Suboxone® (buprenorphine and naloxone) sublingual film and Subutex® (buprenorphine) sublingual tablets, which are approved in multiple countries for the treatment of opioid dependence. In addition to these therapies, Indivior markets Sublocade®, a once-monthly buprenorphine extended-release injectable formulation designed to improve adherence in patients receiving long-term maintenance treatment. Indivior’s robust pipeline features novel formulations and delivery systems aimed at reducing abuse potential and enhancing patient convenience.
Beyond its product portfolio, Indivior engages in collaborative research partnerships with academic institutions and government agencies to explore new approaches to addiction treatment, including medications for stimulant use disorder. The company maintains a global commercial presence, serving markets in North America, Europe, Australia and select emerging markets. Its distribution network leverages partnerships with specialty pharmacies and healthcare providers to support patient education and access programs, ensuring continuity of care across diverse healthcare systems.
Under the leadership of Chief Executive Officer Shaun Thaxter, Indivior continues to prioritize innovation in addiction medicine. The management team includes experienced professionals in regulatory affairs, clinical development and market access, all working to expand the scientific understanding of substance use disorders. With a commitment to social responsibility and evidence-based practice, Indivior aims to address unmet medical needs in addiction treatment and improve long-term outcomes for patients around the world.
AI Generated. May Contain Errors.
